Cirsium oligophyllum

Cirsium oligophyllum: A Comprehensive Reference

1. Identity, Taxonomy, and Botanical Description

Cirsium oligophyllum (Franch. & Sav.) Matsum. is a perennial thistle belonging to the family Asteraceae (formerly Compositae), subfamily Carduoideae, tribe Cardueae, subtribe Carduinae, and genus Cirsium. It is classified within the family Asteraceae, subfamily Carduoideae, tribe Cardueae, subtribe Carduinae, and was formally described by Matsumura in 1895. The species was originally classified as Cnicus oligophyllus Franch. & Sav. before being transferred to the genus Cirsium. The basionym Cnicus oligophyllus was published by Franchet and Savatier in Enumeratio Plantarum Japonicarum 2: 412 (1878). Additional synonyms documented in taxonomic databases include Cirsium autumnale Kitam. and Cirsium tanakae f. obvallatum Nakai.

It is a herbaceous perennial plant growing from a slender rootstock with scarcely developed rhizomes; it produces a basal cluster of leaves and a flowering stem that can grow around 30–120 cm tall. It flowers from August to October, and the seeds ripen from August to October; the species is hermaphrodite (bearing both male and female organs) and is pollinated by insects. It is suitable for light (sandy), medium (loamy), and heavy (clay) soils, and grows to approximately 1 m (3 ft 3 in) in height.

Native range and habitat: The species is native to central Japan (Honshu), occurring in sunny grasslands and along temperate forest margins at elevations from 20 to 1,200 metres. It is a species of thistle native to East Asia, traditionally used in folk medicine for its purported health benefits.

Genus context: The genus Cirsium (family Asteraceae, subfamily Carduoideae) comprises more than 200 species distributed throughout the temperate regions of the Northern Hemisphere. There are around 120 and 50 Cirsium species in Japan and China, respectively.

Common Names and Vernacular Designations

Cirsium oligophyllum does not have a widely standardized English common name in pharmacopeial or regulatory databases. It is sometimes referred to informally as "Japanese thistle" or, in supplements, as "Cirsium oligophyllum extract" (CE). It should not be confused with the better-known milk thistle (Silybum marianum), although it belongs to the same broad botanical family. It is a type of thistle, not to be confused with "milk thistle" or "silymarin" (Silybum marianum), which is more commercially available for liver function.

Preparation Forms

Extracts from the plant's aerial parts have been utilized in teas, tinctures, and topical preparations, often valued for their antioxidant and anti-inflammatory properties. In scientific and commercial contexts, a standardized 30% ethanol aqueous extract of the whole dried plant has been the most rigorously described form. Dried plants of Cirsium oligophyllum were subjected to extraction with a 30% ethanol aqueous solution at room temperature, followed by heating and concentration, to produce the extract (CE) used in research. The plant is also consumed as a food: edible parts include flowers, leaves, oil, and root; young leaves are cooked and added to soups or fried; the root is also consumed cooked. The roots are scraped into pieces, steeped in water, and preserved in miso. The flower heads are fried or used in salads.

In the dietary supplement market, C. oligophyllum extract has been sold in capsule and tablet form, typically as a dry plant extract standardized to a certain percentage of extracted dry matter. As of available records, there is no standard dose for Cirsium oligophyllum.

2. Traditional and Historical Use

East Asian Ethnomedicinal Context

Species of the genus Cirsium have been used as traditional Chinese medicine for hundreds of years; the earliest record is found in the Famous Doctors Records of the Han dynasty, which describes Cirsium as the main remedy for "woman Chibaiwo," calming the fetus, stopping hematemesis, snoring, and bleeding, and "making people fat." To this day, the genus Cirsium is still used clinically as a cold blood hemostatic drug.

Cirsium oligophyllum, a thistle species native to East Asia, has a rich history in traditional medicine, especially within Chinese, Japanese, and Korean herbal practices; it is known for its bioactive compounds, including flavonoids and saponins, and has been valued for centuries as a natural remedy for a wide range of ailments.

Historically, decoctions and extracts from Cirsium oligophyllum were commonly employed to promote blood circulation, reduce inflammation, and support liver health. Traditional healers utilized this plant to manage symptoms of bleeding disorders, such as hemoptysis (coughing up blood), epistaxis (nosebleeds), and excessive menstruation, attributing to it astringent and hemostatic properties. The plant was also applied externally to accelerate wound healing and relieve skin irritation.

Ethnobotanical records from regions such as China and Japan document its application in the form of poultices or topical preparations to support the healing of contusions and minor injuries. The rationale behind its use is largely based on folk practices and the belief that certain thistles possess anti-inflammatory and hemostatic properties.

At present, Cirsium medicinal plants, as traditional Chinese medicine, are mainly used to treat nephritis, Henoch-Schönlein purpura, and hemorrhage, although some species used in folk medicine lack quality control systems.

Food Use

Cirsium oligophyllum is a species of thistle which has long been eaten as a vegetable in a particular area of Asia. The leaves, roots, and stem of Cirsium are edible and can be consumed raw or cooked; the plant can be utilized in salads or in combination with other vegetables; the stem can be peeled and roasted like asparagus. The root is likely to be rich in inulin, a starch that cannot be digested by humans; this starch passes through the digestive system and, in some people, ferments to produce flatulence.

Traditional Preparation Methods

Extracts from the plant's aerial parts have been utilized in teas, tinctures, and topical preparations. In the wider Cirsium genus tradition, in several European countries, the leaves of certain Cirsium species are used to make tea, which is attributed with considerable medicinal properties. The intake of boiled leaves serves as an effective diuretic and liver tonic in traditional usage. A mixture of the soaked leaves and roots of Cirsium has been used as a remedy for the healing of neural problems.

3. Phytochemistry: Key Constituents and Active Compounds

Flavonoids (Principal Class)

The most thoroughly characterized phytochemical group in Cirsium oligophyllum consists of flavone glycosides and their aglycones. A landmark phytochemical study published in the journal Phytochemistry (1999) by Iwashina, Kamenosono, and Ueno reported the definitive isolation and identification of the plant's key flavonoids. Two flavone glycosides — hispidulin 4′-O-β-d-glucopyranoside and nepetin 4′-O-β-d-glucopyranoside — were isolated from the leaves of Cirsium oligophyllum and identified on the basis of ¹H and ¹³C NMR, FAB-MS, UV spectra, and characterization of their hydrolysates; hispidulin 7,4′-glycoside, vicenin-2, hispidulin, and nepetin were also isolated.

The aglycone hispidulin has the formal chemical name 5,7,4′-trihydroxy-6-methoxyflavone. Acid hydrolysis of the main glycoside yielded glucose and hispidulin (5,7,4′-trihydroxy-6-methoxyflavone), which was identified by UV, FAB-mass, and ¹H NMR spectra; hispidulin was also isolated in small amounts as the aglycone from crude extracts. The companion compound nepetin is a closely related methoxyflavone, and its glucoside was simultaneously characterized.

These compounds are also found across other Cirsium species. Common flavones across the Cirsium genus include linarin, luteolin, luteolin 7-O-β-D-glucoside, pectolinarin, apigenin, apigenin 7-O-glucoside, and hispidulin. Vicenin-2, a di-C-glucosylflavone, was specifically isolated from C. oligophyllum alongside the two novel glycosides.

Alkaloid Derivatives

Researchers investigating C. oligophyllum extract identified several alkaloid derivatives, but noted that further investigation is necessary to confirm precise active compounds within this plant. The identity and pharmacological relevance of these alkaloid-class compounds have not been fully elucidated at the time of publication of the primary study.

Inulin (Root)

The root is likely to be rich in inulin, a starch that cannot be digested by humans. Inulin is a well-characterized fructan polysaccharide with prebiotic properties found broadly in the Asteraceae family.

Broader Class Distribution in the Genus

More than 200 chemical constituents including flavonoids, triterpenes, sterols, and phenylpropanoids have been isolated from Cirsium species broadly. While comprehensive phytochemical profiling of C. oligophyllum specifically remains limited in the published literature compared to more-studied species such as C. japonicum, its taxonomic proximity and shared flavonoid chemotaxonomic markers support inference that related compound classes are present.

4. Established and Proposed Mechanisms of Action

β-Adrenergic Receptor–Mediated Lipolysis

The most extensively documented mechanistic finding for C. oligophyllum extract is its ability to promote lipolysis through the β-adrenergic receptor pathway. The activity and action mechanisms of the plant extract (CE) were investigated in isolated adipocytes from rat subcutaneous fat; CE-induced lipolysis was synergistically enhanced by caffeine, a phosphodiesterase inhibitor, and was reduced by propranolol, a β adrenergic antagonist. The suppression of CE-induced lipolysis by propranolol (a non-selective β-blocker) strongly implies that the extract acts, at least in part, via β-adrenergic receptor stimulation. These results indicate that CE promotes lipolysis via a mechanism involving the β adrenergic receptor, and affects body fat mass.

Uncoupling Protein Up-regulation (Thermogenesis)

The fat mass reduction observed with topical application was accompanied by the up-regulation of uncoupling protein 1 (UCP1), a principal thermogenic mitochondrial molecule related to energy dissipation, in subcutaneous fat and UCP3 in skin excluding the fat layer. This fat reduction may be partially due to UCP up-regulation in the skin including subcutaneous fat. UCP1 is the classical thermogenin of brown adipose tissue; its induction in subcutaneous fat is associated with conversion of white adipocytes toward a more thermogenic phenotype.

Antioxidant Activity

Hispidulin and nepetin — the principal flavonoids isolated from C. oligophyllum — possess established antioxidant properties on the basis of their polyphenolic structures. Flavonoids are a kind of polyphenol present in medicinal plants that have been shown to have antioxidant and anticancer effects. Across the Cirsium genus, pharmacological research studies have revealed that Cirsium is valued for its wide range of therapeutic benefits, including hepatoprotection, antioxidant activity, anticancer activity, antimicrobial activity, and anti-inflammation.

Anti-inflammatory Mechanisms

Pharmacological studies have revealed that Cirsium species have several biological activities, including hepatoprotective, antibacterial, antioxidant, antitumor, and anti-inflammatory activities, which help explain the various traditional applications of the Cirsium genus. Specific anti-inflammatory mechanisms at the molecular level (e.g., inhibition of nitric oxide or pro-inflammatory cytokines) have been studied principally in other Cirsium species such as C. japonicum; direct experimental evidence from C. oligophyllum in this domain remains limited.

Hemostatic Properties

Cirsium plants are used in traditional Chinese medicine for their therapeutic properties, including cooling blood, stopping bleeding, and dispelling blood stasis; they have been shown to possess various pharmacological effects such as hepatoprotection, antioxidant, and anti-inflammatory activities, making them significant in the treatment of conditions like nephritis and hemorrhage. These hemostatic effects have been attributed broadly to the flavonoid and phenylpropanoid content of the genus.

5. Scientific Evidence by Area of Use

5.1 Body Fat Reduction and Lipolysis

Summary of evidence: Preliminary; animal/in vitro data only; no human clinical trials confirmed.

The primary and most cited study on C. oligophyllum in the context of body fat metabolism was published in 2009 in the International Journal of Biological Sciences by Mori et al., conducted at the Biological Science Laboratories, Kao Corporation, Japan (PMC2677732). The activities and action mechanisms of a novel plant extract of Cirsium oligophyllum (CE) were investigated in isolated adipocytes from rat subcutaneous fat, and its fat-reducing effects by peroral administration and topical application were evaluated in vivo.

In vitro findings: CE was selected as a natural product with marked lipolysis-promoting effects in isolated subcutaneous adipocytes; experiments using the phosphodiesterase (PDE) inhibitor and β antagonist showed that CE could directly promote adipose lipolysis.

Oral in vivo (rat) findings: Peroral administration of a 10% CE solution to Wistar rats for 32 days reduced body weight gain, subcutaneous fat weight, and visceral fat weight by 6.6%, 26.2%, and 3.0%, respectively, as compared to the control group.

Topical in vivo (rat) findings: By the topical application of 2% of this extract to rats for 7 days, weight of subcutaneous fat in the treated skin was reduced by 23.2%.

Caffeine synergy: CE-induced lipolysis was synergistically enhanced by caffeine, a phosphodiesterase inhibitor. This finding has driven commercial interest in combining C. oligophyllum with caffeine in supplement products.

Significance assessment: The authors explicitly described this as "the first report showing that repeated lipolysis promotion through CE administration may be beneficial for the systematic suppression of body fat accumulation or the control of fat distribution in obesity." However, this study was conducted on rats (not humans) and was purely concerned with the mechanism of action responsible for Cirsium oligophyllum's lipolysis-promoting activities. No controlled human clinical trials investigating body composition outcomes with C. oligophyllum extract have been reported in the peer-reviewed literature.

5.2 Antioxidant Activity

Summary of evidence: In vitro and animal data; no direct human trials for C. oligophyllum specifically.

Antioxidant activity in the Cirsium genus has been broadly demonstrated. Recent studies have pointed out that Cirsium species possess anticancer, antidiabetic, hepatoprotective, renoprotective, and neuroprotective effects through their antioxidant activities. The flavonoid constituents of C. oligophyllum — hispidulin and nepetin — are structurally well-positioned to act as free radical scavengers. Tracin, luteolin, and hispidulin exhibited marked protective efficacy against bacterial strains, and this antibacterial protective efficacy is partially linked to their antioxidant mechanisms. Direct antioxidant assays specifically for C. oligophyllum are not independently reported in the current peer-reviewed literature beyond inference from genus-level data.

5.3 Hepatoprotective Activity

Summary of evidence: Preclinical (animal) data from related species; no species-specific human trial data for C. oligophyllum.

Cirsium plants are considered an excellent and harmless agent for the cure of liver diseases; therefore, they might be a good clinical option for the development of therapeutics for hepatic infections. Crude extracts of Cirsium normalized the levels of SGOT and SGPT in mice raised by CCl4 injection; Cirsium japonicum and Cirsii herba decreased CCl4-stimulated liver necrosis and restored the levels of hepatic antioxidant enzymes and malondialdehyde. These findings are from related species and have not been replicated in independent clinical trials for C. oligophyllum specifically. Few phytochemistry studies were quantitatively and qualitatively carried out, leaving a knowledge gap between phytochemistry and clinical applications.

5.4 Anti-inflammatory Activity

Summary of evidence: In vitro and preclinical animal evidence from the genus; preliminary only.

Pharmacological studies revealed that Cirsium species have biological activities including hepatoprotective, antibacterial, antioxidant, antitumor, and anti-inflammatory. One area of focus is anti-inflammatory properties; extracts from Cirsium oligophyllum have shown promise in reducing inflammation in laboratory tests. However, studies are required on less-known Cirsium species, particularly on the elucidation of the mode of action of their activities. No clinical trials in humans have been published specifically for C. oligophyllum addressing inflammatory conditions.

5.5 Antimicrobial Activity

Summary of evidence: In vitro only; preliminary.

Another potential application is in the field of antimicrobial medicine; preliminary research has indicated that certain compounds in C. oligophyllum may have antimicrobial activity against a range of bacteria and fungi. Within the broader genus, tracin, luteolin, and hispidulin exhibited marked protective efficacy against bacterial strains. No peer-reviewed in vivo or clinical antimicrobial data specific to C. oligophyllum have been independently confirmed.

5.6 Hemostasis and Bleeding Disorders

Summary of evidence: Traditional use corroborated by genus-level preclinical data; no human clinical evidence for C. oligophyllum specifically.

Many species of Cirsium are exploited as herbal remedies for cardiovascular diseases and used as anti-inflammatory and diuretic agents traditionally; Cirsium is still employed clinically as a cold blood hemostatic medicine. Cirsium medicinal plants, as traditional Chinese medicine, are mainly used to treat nephritis, Henoch-Schönlein purpura, and hemorrhage. For C. oligophyllum specifically, the hemostatic application rests on traditional ethnomedicinal use rather than controlled clinical evidence.

5.7 Bruise Healing and Wound Healing

Summary of evidence: Traditional/ethnobotanical only; no modern scientific validation.

There is a lack of robust scientific studies or clinical trials specifically evaluating Cirsium oligophyllum for bruise healing; most available evidence remains anecdotal or is based on traditional herbal compendia, rather than pharmacological validation. Phytochemical investigations have identified certain flavonoids and other bioactive compounds in related Cirsium species which may contribute to anti-inflammatory effects, but the evidence rating is low due to the absence of controlled studies or rigorous pharmacological data.

6. Body Systems and Health Areas of Association

• Adipose tissue / Metabolic: Lipolysis stimulation, β-adrenergic signaling, UCP1/UCP3 thermogenesis, body fat mass modulation — based on animal studies.
• Liver / Hepatic: Hepatoprotective potential attributed to flavonoid and polyphenol content — genus-level evidence.
• Cardiovascular / Circulatory: Traditional use for blood stasis, promotion of circulation, hemostatic applications — ethnomedicinal.
• Immune / Inflammatory: Anti-inflammatory activity in vitro; antioxidant mechanisms involving hispidulin, nepetin, and related flavones.
• Hematological: Used historically for hemostasis and hemorrhage control in TCM practice.
• Skin: Topical preparations used traditionally for wound healing and bruises; UCP3 up-regulation in skin observed in animal studies following topical application.
• Digestive: Consumed as a food; inulin content in root may have prebiotic effects; some traditional use for digestive support noted broadly within the genus.

7. Dosage Forms and Dosages Reported in Studies

No clinically validated human dosage has been established for Cirsium oligophyllum. There is no standard dose for Cirsium oligophyllum. The following dosages appear only in animal research and should not be interpreted as human-applicable therapeutic doses.

• Oral (rat, body fat study): Peroral administration of a 10% CE (extracted dry matter) solution administered to Wistar rats for 32 days resulted in reductions in body weight gain and fat depots.
• Topical (rat): Topical application of a 2% extract concentration to rats for 7 days resulted in a 23.2% reduction in weight of subcutaneous fat in the treated skin area.
• Extraction method: Dried plant material was subjected to extraction with a 30% ethanol aqueous solution at room temperature, followed by heating and concentration.
• Commercial supplement: One supplement formulation containing C. oligophyllum has been reported to include 750 mg of CE per serving, though this is product-specific and not derived from a clinical trial protocol.

8. Safety Considerations and Known Interactions

Absence of Dedicated Safety Data

In-depth toxicity studies are lacking for Cirsium oligophyllum whole plant extract. Before any widespread use in medicine or other applications, it is crucial to determine the toxicity of the extract; this includes acute toxicity studies to see the immediate effects of high-dose exposure and chronic toxicity studies to understand the long-term effects of repeated exposure. The lack of toxicity data represents a major obstacle in the development of pharmaceutical products from the plant extract.

A systemic safety study of Cirsium extract is required for the expansion of novel pharmaceuticals or drugs.

Analog Species Safety Data

While no dedicated acute or chronic toxicity studies have been published for C. oligophyllum itself, a closely related edible Korean species, Cirsium setidens, has been studied. No animal deaths or abnormal clinical signs were observed during a formal acute toxicity study; there were no significant changes in body weight, and no abnormalities were found during necropsy, suggesting that the C. setidens extract is essentially non-toxic after acute exposure. Additionally, no significant adverse effects on body weight, mortality, or gross findings were observed for 15 days after a single dose (2,000 mg of extracts/kg body weight) of Cirsium japonicum extract in acute toxicity assessment. These data from congeners provide some indirect contextual reassurance but cannot be directly applied to C. oligophyllum.

Asteraceae Hypersensitivity

Individuals with known hypersensitivity to plants in the family Asteraceae (e.g., ragweed, chrysanthemum, chamomile, echinacea) may be at risk of cross-reactive allergic responses to any Cirsium species product, consistent with the known class sensitization profile of the botanical family. This class-level concern is recognized across Asteraceae-family preparations in pharmacological literature.

β-Adrenergic Receptor Mechanism Implications

Given that CE was shown to act via β-adrenergic receptor stimulation and that its effects were reduced by the β-blocker propranolol, the extract's lipolysis-promoting activity was found to be synergistically enhanced by caffeine and reduced by propranolol, indicating a dependency on the β adrenergic receptor for its fat-reducing effects. From a pharmacological standpoint, this mechanism carries theoretical cardiovascular implications — including potential interaction with beta-adrenergic blocking medications (beta-blockers) and additive cardiovascular stimulant effects when combined with caffeine or other adrenergic agents — though no human safety data confirming these interactions in vivo have been published.

Caffeine Interaction

CE-induced lipolysis was synergistically enhanced by caffeine, a phosphodiesterase inhibitor. This synergy was utilized in the design of combination thermogenic supplement products. Individuals sensitive to stimulant compounds should note that formulations combining C. oligophyllum with caffeine may produce additive adrenergic effects, though the magnitude and clinical significance of this interaction in humans has not been formally studied.

Regulatory and Quality Considerations

The NIH Dietary Supplement Label Database (DSLD) documents Cirsium oligophyllum as an ingredient found in U.S.-marketed dietary supplement products, but no official monograph from WHO, EMA, ESCOP, German Commission E, EFSA, or USP has been published for this species. The available data remain methodologically heterogeneous; studies often differ in the plant parts used, extraction procedures, analytical techniques, and experimental models, complicating comparisons between studies and limiting a comprehensive evaluation of pharmacological potential.

9. Summary of Evidence Strength

• Phytochemistry: Well-characterized at the flavone glycoside level (hispidulin and nepetin glucosides) based on published peer-reviewed analytical studies (Iwashina et al., 1999, Phytochemistry).
• Lipolysis / Fat Loss: One peer-reviewed preclinical study in rats (Mori et al., 2009, Int J Biol Sci); no human clinical data. Evidence strength: weak (animal-only).
• Anti-inflammatory / Antioxidant: Extrapolated from genus-level and in vitro data; no species-specific clinical trials. Evidence strength: very preliminary.
• Hemostatic / Hepatoprotective: Supported by traditional use and genus-level preclinical evidence; no C. oligophyllum-specific controlled studies. Evidence strength: insufficient for clinical claims.
• Human safety: No formal toxicological studies. Evidence strength: not established.

References

• Mori S, et al. "Body fat mass reduction and up-regulation of uncoupling protein by novel lipolysis-promoting plant extract." Int J Biol Sci. 2009;5(4):311–318. PMC2677732
• Mori S, et al. Body fat mass reduction and up-regulation of uncoupling protein by novel lipolysis-promoting plant extract. PubMed abstract. PMID 19421341
• Iwashina T, Kamenosono K, Ueno T. "Hispidulin and nepetin 4′-glucosides from Cirsium oligophyllum." Phytochemistry. 1999;51:1109–1111. ScienceDirect
• Aggarwal G, et al. "Traditional Uses, Phytochemical Composition, Pharmacological Properties, and the Biodiscovery Potential of the Genus Cirsium." Chemistry 2022, 4, 1161–1192. MDPI
• ScienceDirect Topics / Journal of Ethnopharmacology 2021: Recent research progress of Cirsium medicinal plants in China
• Comparison of the Hepatoprotective Effects of Four Endemic Cirsium Species Extracts from Taiwan on CCl4-Induced Acute Liver Damage in C57BL/6 Mice. PMC5983772
• Antioxidant Effects and Phytochemical Properties of Seven Taiwanese Cirsium Species Extracts. PMC8272034
• Acute and 4-Week Repeated-Dose Oral Toxicity Studies of Cirsium setidens in Rats. PMC6271068
• Cirsium brevicaule A. GRAY leaf inhibits adipogenesis in 3T3-L1 cells and C57BL/6 mice. PMC3751477
• Cirsium arvense and Cirsium vulgare: Comparative Ethnopharmacology, Phytochemistry and Pharmacological Review. Molecules 2026. DOI: 10.3390/molecules31071211
• Plants of the World Online — Cirsium oligophyllum var. oligophyllum. Kew Science
• Cirsium oligophyllum. Wikispecies / Species 2000 & ITIS Catalogue of Life
• Cirsium oligophyllum — Plants For A Future (PFAF) Database
• Cirsium oligophyllum — Useful Temperate Plants Database, Ken Fern
• NIH Dietary Supplement Label Database (DSLD) — Cirsium oligophyllum ingredient page
• Shim SM, et al. "Single-dose oral acute toxicity and mutagenic effects of methanol extracts of Cirsium japonicum." J Food Biochem. 2011. Wiley Online Library
• Iwashina T. Flavonoids Isolated from Cirsium Taxa and Carduus. Bulletin of the National Museum of Nature and Science, Tokyo
• Mori S, et al. Body fat mass reduction and up-regulation of uncoupling protein by novel lipolysis-promoting plant extract. Int J Biol Sci 2009;5(4):311–318 (publisher page)